全文获取类型
收费全文 | 51184篇 |
免费 | 4206篇 |
国内免费 | 1985篇 |
专业分类
耳鼻咽喉 | 368篇 |
儿科学 | 937篇 |
妇产科学 | 793篇 |
基础医学 | 8307篇 |
口腔科学 | 1860篇 |
临床医学 | 4781篇 |
内科学 | 7979篇 |
皮肤病学 | 1563篇 |
神经病学 | 2703篇 |
特种医学 | 961篇 |
外国民族医学 | 7篇 |
外科学 | 3057篇 |
综合类 | 7083篇 |
现状与发展 | 10篇 |
预防医学 | 2869篇 |
眼科学 | 1039篇 |
药学 | 8826篇 |
20篇 | |
中国医学 | 2106篇 |
肿瘤学 | 2106篇 |
出版年
2024年 | 154篇 |
2023年 | 822篇 |
2022年 | 1589篇 |
2021年 | 2135篇 |
2020年 | 1773篇 |
2019年 | 1683篇 |
2018年 | 1670篇 |
2017年 | 1758篇 |
2016年 | 1778篇 |
2015年 | 1916篇 |
2014年 | 2880篇 |
2013年 | 3958篇 |
2012年 | 2697篇 |
2011年 | 3111篇 |
2010年 | 2636篇 |
2009年 | 2448篇 |
2008年 | 2526篇 |
2007年 | 2619篇 |
2006年 | 2290篇 |
2005年 | 2229篇 |
2004年 | 1854篇 |
2003年 | 1650篇 |
2002年 | 1433篇 |
2001年 | 1247篇 |
2000年 | 1105篇 |
1999年 | 1036篇 |
1998年 | 961篇 |
1997年 | 837篇 |
1996年 | 681篇 |
1995年 | 689篇 |
1994年 | 586篇 |
1993年 | 457篇 |
1992年 | 393篇 |
1991年 | 275篇 |
1990年 | 187篇 |
1989年 | 144篇 |
1988年 | 136篇 |
1987年 | 122篇 |
1986年 | 96篇 |
1985年 | 129篇 |
1984年 | 131篇 |
1983年 | 106篇 |
1982年 | 92篇 |
1981年 | 88篇 |
1980年 | 64篇 |
1979年 | 51篇 |
1978年 | 31篇 |
1977年 | 41篇 |
1976年 | 39篇 |
1973年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
欧洲药品局(EMA)于2018年11月发布了"人用药品辅料右旋糖酐的包装说明书资料",该文件引用大量文献全面评价了右旋糖酐的安全性,特别指出含有右旋糖酐辅料的注射和吸入制剂的疫苗与药品,应在说明书中描述有关其过敏反应信息的新要求。介绍该文件的主要内容,期望对我国这类药品说明书的撰写和监管有所帮助。 相似文献
2.
《Vaccine》2019,37(31):4382-4391
Cancer-associated fibroblasts (CAFs), major components of the tumor microenvironment (TME), promote tumor growth and metastasis and inhibit the anti-tumor immune response. We previously constructed a DNA vaccine expressing human FAPα, which is highly expressed by CAFs, to target these cells in the TME, and observed limited anti-tumor effects in the 4T1 breast cancer model. When the treatment time was delayed until tumor nodes formed, the anti-tumor effect of the vaccine completely disappeared. In this study, to improve the safety and efficacy, we constructed a new FAPα-targeted vaccine containing only the extracellular domain of human FAPα with a tissue plasminogen activator signal sequence for enhanced antigen secretion and immunogenicity. The number of CAFs was more effectively reduced by CD8+ T cells induced by the new vaccine. This resulted in decreases in CCL2 and CXCL12 expression, leading to a significant decrease in the ratio of myeloid-derived suppressor cells in the TME. Moreover, when mice were treated after the establishment of tumors, the vaccine could still delay tumor growth. To facilitate the future application of the vaccine in clinical trials, we further optimized the gene codons and reduced the homology between the vaccine and the original sequence, which may be convenient for evaluating the vaccine distribution in the human body. These results indicated that the new FAPα-targeted vaccine expressing an optimized secreted human FAPα induced enhanced anti-tumor activity by reducing the number of FAPα+ CAFs and enhancing the recruitment of effector T cells in the 4T1 tumor model mice. 相似文献
3.
目的分析托珠单抗的安全性风险,为临床合理用药提供参考。方法对世界卫生组织药品不良反应监测数据库、我国药品不良反应监测数据库、国内文献数据库中的不良反应报告情况及国外药监机构风险控制措施等相关资料进行整理与分析。结果应重视托珠单抗临床使用中可能发生的肝功能异常、皮肤损害、过敏反应、胃肠道损害、感染、血液系统损害等不良反应。结论托珠单抗临床使用中,应加强对严重感染及肝功能损害等严重不良反应的安全性监测,促进药品的临床合理使用。 相似文献
4.
5.
陈振华 《中国卫生标准管理》2020,(8):76-79
目的探讨儿童流感应用帕拉米韦注射液治疗的临床疗效以及用药安全性。方法随机选定在2016年1月-2019年1月期间佛山市高明区人民医院儿科住院治疗并确诊流感A或B型患儿200例,通过随机数字法将其分为治疗组和对照组。治疗组100例用帕拉米韦注射液治疗,对照组100例用国产磷酸奥司他韦颗粒治疗,评价两组患儿治疗前后症状评分、治疗效果、治疗指标以及不良反应发生情况。结果两组患儿治疗前流感样症状评分无统计学意义(P>0.05),两组患儿治疗后较治疗前流感样症状评分均下降,差异有统计学意义(P<0.05);治疗组治疗后流感样症状评分略小于对照组,但是无统计学意义(P>0.05);治疗组治疗总有效率高于对照组,治疗组患儿发热症状缓解、全部症状缓解以及住院时间均小于对照组,存在统计学意义(P<0.05)。治疗组与对照组不良反应发生率较低,且无统计学意义(P>0.05)。结论帕拉米韦注射液可用于儿童流感治疗,不仅能够保证临床疗效,而且可加快症状缓解,同时存在较高用药安全性。 相似文献
6.
光化学作用对肿瘤细胞胞吞大分子的释放 总被引:1,自引:0,他引:1
目的观察不同光敏剂在肿瘤细胞内的分布,以及光化学作用对肿瘤细胞胞吞大分子的释放作用.方法使用激光共聚焦显微镜观察ALA、ALA-HE、HMME、TPPSa2在肿瘤细胞SW480、K562的胞内分布,使用FITC-右旋糖酐观察肿瘤细胞对荧光标记大分子的胞吞作用,通过光照激发光敏化细胞,动态观察光化学作用前后胞吞大分子FITC-右旋糖酐的胞内分布变化.结果ALA、ALA-HE、HMME、TPPSa24种光敏剂均表现为胞质分布,核内分布少.ALA、ALA-HE的胞内分布主要表现为胞质内的弥散性荧光.HMME则表现为胞质内颗粒状荧光与弥散荧光同时存在.TPPSa2为典型的胞质内颗粒状荧光分布.光敏剂在SW480、K562两种肿瘤细胞的胞内分布没有明显差异.光照激发不同光敏剂对肿瘤细胞胞吞FITC-左旋糖酐的胞内分布影响不同.由TPPSa2及HMME活化而产生的光化学作用表现出明显的荧光颗粒重分布,ALA、ALA-HE则对胞吞荧光无明显重分布作用.结论不同光敏剂因其不同的理化性质而表现为不同的胞内分布.光化学作用可对肿瘤细胞胞吞大分子产生胞吞释放作用,其作用机制可能与光化学作用对胞吞泡的破坏有关. 相似文献
7.
Attila Szalmas Peter Bodrogi Cecilia Sik-Lanyi 《Ophthalmic & physiological optics》2006,26(3):281-287
The objective of this study is to test the luminous efficiency functions V(lambda), V'(lambda), V(10)(lambda) and their linear combinations on the basis of a data set gained from a simulated mesopic night-time driving experiment. Another aim is to provide 'real-world' data for the 'X framework' or 'linear combination model', and to find out its limits in a practical situation. Human performance was measured by the reaction time method. Results show that the single parameter of the linear combination of photopic and scotopic luminous efficiency functions can be determined analytically with little variation for a given mesopic background luminance level and a given visual target colour, but the computation leads to considerable deviations comparing all three target colours (red, green and blue) used in the experiment. The conclusion for the given experimental conditions is that the single parameter of the linear combination model has an increasing deviation for lower background luminance levels. 相似文献
8.
香菇多糖抗炎作用的实验研究 总被引:5,自引:0,他引:5
目的:研究香菇多糖的抗炎作用。方法:用二甲苯所致小鼠耳肿胀、鸡蛋清所致小鼠足跖肿胀等急性炎症以及滤纸片诱发小鼠肉芽组织增生所致小鼠慢性炎症模型进行试验。结果:香菇多糖能抑制二甲苯所致的小鼠耳肿、鸡蛋清所致小鼠足跖肿胀;与此同时对滤纸片诱发小鼠肉芽组织增生形成有抑制作用。结论:香菇多糖具有一定抑制急慢性炎症反应作用。其抗炎作用的机制,值得进一步研究。 相似文献
9.
10.
BACKGROUND: Levels of an immunoregulatory and anti-inflammatory cytokine IL-10 are reduced in asthmatic airways, potentially contributing to more intense inflammation. Triamcinolone has anti-inflammatory properties and the anti-inflammatory effects of montelukast and formoterol have been discussed. OBJECTIVE: The purpose of this study was to define the effect of treatment with triamcinolone, montelukast and formoterol on the serum level of IL-10, eosinophil blood counts, eosinophil cationic response (ECP) and clinical parameters (symptom score, FEV1 and PC20H) in children with moderate asthma. METHODS: An 8-week, placebo-controlled and randomized, double-blind trial was carried out. The subjects were 91 children with moderate atopic asthma who were allergic to dust mite. Patients were randomly allocated to receive 400 microg triamcinolone (n = 19), 5 or 10 mg (according to age) montelukast (n = 18), 24 microg formoterol (n = 18) or placebo (n = 36). RESULTS: Seventy-nine children completed the study. After treatment with triamcinolone and montelukast the level of IL-10 in blood serum significantly increased, eosinophil blood counts and ECP levels significantly decreased and all clinical parameters improved; treatment with formoterol had no effect on IL-10 level, eosinophil blood counts in serum and bronchial hyper-reactivity; ECP level significantly decreased after treatment and asthma symptoms and FEV1 improved significantly. Mean IL-10 levels in serum before and after treatment with triamcinolone were 7.23 pg/mL with 95% CI, 6.74 -7.72% and 14.24 pg/mL with 95% CI, 11.6-16.88%, respectively (P < 0.001); with montelukast they were 6.59 pg/mL with 95% CI, 6.26-7.23% and 10.94 pg/mL with 95% CI, 8.24-12.65%, respectively (P < 0.002); with formoterol they were 7.06 pg/mL with 95% CI, 6.61-7.52% and 7.04 pg/mL with 95% CI, 6.15-7.93%. We found statistically significant correlations between serum level of IL-10 and serum level of ECP after treatment with triamcinolone and montelukast. CONCLUSION: This study demonstrates that one possible way by which triamcinolone and montelukast contribute to inhibition of inflammation is by increasing IL-10 levels. 相似文献